Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia

Hypertension in Pregnancy

Volumn 33, Issue 4, 2014, Pages 427-439

  Baltajian, Kedak ^a   Hecht, Jonathan L ^b   Wenger, Julia B ^b   Salahuddin, Saira ^a   Verlohren, Stefan ^c   Perschel, Frank H ^c   Zsengeller, Zsuzsanna K ^b   Thadhani, Ravi ^b   Karumanchi, S Ananth ^a,b,d   Rana, Sarosh ^a  

^a Division of Maternal Fetal Medicine   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Angiogenic factors; Placenta; Placental lesions

Indexed keywords

ANGIOGENIC FACTOR; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FETAL THROMBOSIS; GESTATIONAL AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MEASUREMENT; PLACENTA ATHEROSIS; PLACENTA HEMATOMA; PLACENTA INSUFFICIENCY; PLACENTAL INFARCT; PREECLAMPSIA; PROTEIN BLOOD LEVEL; SOLUTIO PLACENTAE; SYNCYTIAL KNOT; SYSTOLIC BLOOD PRESSURE; BLOOD; COHORT ANALYSIS; PATHOLOGY; PLACENTA; PREGNANCY; YOUNG ADULT;

ADULT; COHORT STUDIES; FEMALE; HUMANS; PLACENTA; PLACENTAL INSUFFICIENCY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84911477945     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2014.926914     Document Type: Article

References (37)

1. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008;21:521-6.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
3. Sliwa K, Ojji D, Bachelier K, et al. Hypertension and hypertensive heart disease in African women. Clin Res Cardiol 2014;103:515-23.
4. Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 1995;172:1785-8; discussion 8-92.
5. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
6. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern-Fetal Neonatal Med: Official J Eur Assoc Perinat Med, Feder Asia Ocean Perinat Soc, Int Soc Perinat Obstet 2014;27:132-44.
7. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
8. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern-Fetal Neonatal Med: Official J Eur Assoc Perinat Med Feder Asia Ocean Perinat Soc Int Soc Perinat Obstet 2008;21:9-23.
9. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern-Fetal Neonatal Med: Official J Eur Assoc Perinat Med Feder Asia Ocean Perinat Soc Int Soc Perinat Obstet 2009;22:1021-38.
10. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121-31.
11. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911-19.
12. Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern-Fetal Neonatal Med: Official J Eur Assoc Perinat Med Feder Asia Ocean Perinat Soc Int Soc Perinat Obstet 2012;25:2651-7.
13. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013;208:287 e1-15.
14. Rana S, Schnettler WT, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnan: Official J Int Soc Study of Hypertens Pregnan 2013;32:189-201.
15. Ghidini A, Salafia CM, Pezzullo JC. Placental vascular lesions and likelihood of diagnosis of preeclampsia. Obstet Gynecol 1997;90:542-5.
16. Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Hypertens 2012;2:72-83.
17. Bujold E, Romero R, Chaiworapongsa T, et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern-Fetal Neonatal Med: Official J Eur Assoc Perinat Med Feder Asia Ocean Perinat Soc Int Soc Perinat Obstet 2005;18:9-16.
18. Buurma AJ, Penning ME, Prins F, et al. Preeclampsia is associated with the presence of transcriptionally active placental fragments in the maternal lung. Hypertension 2013;62:608-13.
19. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
20. Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59:740-6.
21. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013;13:59.
22. Kraus FT. Placental pathology (atlas of nontumor pathology). 1st ed. Washington, DC: American Registry of Pathology; 2004.
23. Silasi M, Rana S, Powe C, et al. Placental expression of angiogenic factors in Trisomy 13. Am J Obstet Gynecol 2011;204:546 e1-4.
24. Rajakumar A, Cerdeira AS, Rana S, et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012;59:256-64.
25. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818-24.
26. Gomez-Arriaga PI, Herraiz I, Lopez-Jimenez EA, et al. Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness for the prognosis assessment of early-onset preeclampsia. Ultrasound Obstet Gynecol 2014;43:525-32.
27. Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern-Fetal Neonatal Med: Official J Eur Assoc Perinat Med Feder Asia Ocean Perinat Soc Int Soc Perinat Obstet 2008;21:25-40.
28. Whitten AE, Romero R, Korzeniewski SJ, et al. Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol 2013;208:310 e1-11.
29. Schoofs K, Grittner U, Engels T, et al. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 2014;42:61-8.
30. Nelson DB, Ziadie MS, McIntire DD, et al. Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol 2014;210:66 e1-7.
31. Moldenhauer JS, Stanek J, Warshak C, et al. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003;189:1173-7.
32. Sebire NJ, Goldin RD, Regan L. Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol 2005;25:117-18.
33. Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013;61:932-42.
34. Mateus JGN, Longo M, Saade GR, et al. Placental histopathology in mild versus severe hypertensive disorders in pregnancy: implications for feto-placental perfusion. Am J Obstet Gynecol 2008;100:S215.
35. de Almeida Pimenta EJ, Silva de Paula CF, Duarte Bonini Campos JA, et al. Three-dimensional sonographic assessment of placental volume and vascularization in pregnancies complicated by hypertensive disorders. J Ultrasound Med 2014;33:483-91.
36. Parikh SM, Karumanchi SA. Putting pressure on pre-eclampsia. Nat Med 2008;14:810-12.
37. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 2014;63:198-202.